Antifungal combination therapy in invasive fungal infections;Associations antifongiques dans les infections fongiques invasives

Revue de Medecine Interne

Volumn 31, Issue 1, 2010, Pages 72-81

  Gellen Dautremer, J ^a   Lanternier, F ^b   Dannaoui, E ^c,d   Lortholary, O ^b,c  

^a BEAUJON HOSPITAL   (France)

^b HÔPITAL NECKER ENFANTS MALADES   (France)

^c CNRS   (France)

^d HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

Antifungal combination therapy; Aspergillosis; Candidemia; Cryptococcosis

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; ANTIFUNGAL AGENT; CASPOFUNGIN; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; PLACEBO; POLYENE; POSACONAZOLE; PYRROLE DERIVATIVE; VORICONAZOLE;

ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ASPERGILLOSIS; ASPERGILLUS; CANDIDA; CANDIDIASIS; CRYPTOCOCCAL MENINGITIS; CRYPTOCOCCOSIS; CRYPTOCOCCUS; DISEASE SEVERITY; DRUG POTENTIATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE DEFICIENCY; MEDICAL EXPERT; MEDICAL RESEARCH; MORBIDITY; MORTALITY; MYCOSIS; PRACTICE GUIDELINE; PROGNOSIS; SHORT SURVEY;

ANTIFUNGAL AGENTS; ASPERGILLOSIS; CANDIDIASIS; CRYPTOCOCCOSIS; DRUG THERAPY, COMBINATION; HUMANS; MYCOSES; PRACTICE GUIDELINES AS TOPIC;

EID: 73549112676     PISSN: 02488663     EISSN: 17683122     Source Type: Journal    
DOI: 10.1016/j.revmed.2009.02.027     Document Type: Short Survey

References (60)

1. Tortorano A.M., Kibbler C., Peman J., Bernhardt H., Klingspor L., and Grillot R. Candidaemia in Europe: epidemiology and resistance. Int J Antimicrob Agents 27 (2006) 359-366
2. Leroy O.G.J., Montravers P., Mira J.P., Gouin F., Sollet J.P., Carlet J., et al. Epidemiology, management and risk factors for death of invasive Candida infections in critical care: a multicenter, prospective, observational study in France (2005-2006). Crit Care Med (2007) revised
3. Cornillet A., Camus C., Nimubona S., Gandemer V., Tattevin P., Belleguic C., et al. Comparison of epidemiological, clinical, and biological features of invasive aspergillosis in neutropenic and nonneutropenic patients: a 6-year survey. Clin Infect Dis 43 (2006) 577-584
4. Micol R., Lortholary O., Sar B., Laureillard D., Ngeth C., Dousset J.P., et al. Prevalence, determinants of positivity, and clinical utility of cryptococcal antigenemia in Cambodian HIV-infected patients. J Acquir Immune Defic Syndr 45 (2007) 555-559
5. Lortholary O., Poizat G., Zeller V., Neuville S., Boibieux A., Alvarez M., et al. Long-term outcome of AIDS-associated cryptococcosis in the era of combination antiretroviral therapy. AIDS 20 (2006) 2183-2191
6. Herbrecht R., Denning D.W., Patterson T.F., Bennett J.E., Greene R.E., Oestmann J.W., et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 347 (2002) 408-415
7. Rex J.H., Pappas P.G., Karchmer A.W., Sobel J., Edwards J.E., Hadley S., et al. A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. Clin Infect Dis 36 (2003) 1221-1228
8. Saag M.S., Graybill R.J., Larsen R.A., Pappas P.G., Perfect J.R., Powderly W.G., et al. Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America. Clin Infect Dis 30 (2000) 710-718
9. Cornely O.A., Maertens J., Bresnik M., Ebrahimi R., Ullmann A.J., Bouza E., et al. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis 44 (2007) 1289-1297
10. Walsh T.J., Raad I., Patterson T.F., Chandrasekar P., Donowitz G.R., Graybill R., et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis 44 (2007) 2-12
11. Maertens J., Raad I., Petrikkos G., Boogaerts M., Selleslag D., Petersen F.B., et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 39 (2004) 1563-1571
12. Regnier B.A.M., Bezie Y., Blanc V., Buzyn A., Choutet P., Mimoz O., et al. Prise en charge des aspergilloses et candidoses invasives de l'adulte. Conférence de consensus commune SFAR, SPILF, SRLF. Ann Fr Anesth Reanim (2004) 5-13 [numéro special]
13. Pappas P.G., Kauffman C.A., Andes D., Benjamin Jr. D.K., Calandra T.F., Edwards J., et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 48 (2009) 503-535
14. Dannaoui E., Lortholary O., and Dromer F. In vitro evaluation of double and triple combinations of antifungal drugs against Aspergillus fumigatus and Aspergillus terreus. Antimicrob Agents Chemother 48 (2004) 970-978
15. Bennett J.E., Dismukes W.E., Duma R.J., Medoff G., Sande M.A., Gallis H., et al. A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptoccal meningitis. N Engl J Med 301 (1979) 126-131
16. van der Horst C.M., Saag M.S., Cloud G.A., Hamill R.J., Graybill J.R., Sobel J.D., et al. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Gro*up and AIDS Clinical Trials Group. N Engl J Med 337 (1997) 15-21
17. Dismukes W.E., Cloud G., Gallis H.A., Kerkering T.M., Medoff G., Craven P.C., et al. Treatment of cryptococcal meningitis with combination amphotericin B and flucytosine for four as compared with six weeks. N Engl J Med 317 (1987) 334-341
18. Larsen R.A., Leal M.A., and Chan L.S. Fluconazole compared with amphotericin B plus flucytosine for cryptococcal meningitis in AIDS. A randomized trial. Ann Intern Med 113 (1990) 183-187
19. Larsen R.A., Bozzette S.A., Jones B.E., Haghighat D., Leal M.A., Forthal D., et al. Fluconazole combined with flucytosine for treatment of cryptococcal meningitis in patients with AIDS. Clin Infect Dis 19 (1994) 741-745
20. Brouwer A.E., Rajanuwong A., Chierakul W., Griffin G.E., Larsen R.A., White N.J., et al. Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial. Lancet 363 (2004) 1764-1767
21. Te Dorsthorst D.T., Verweij P.E., Meletiadis J., Bergervoet M., Punt N.C., Meis J.F., et al. In vitro interaction of flucytosine combined with amphotericin B or fluconazole against thirty-five yeast isolates determined by both the fractional inhibitory concentration index and the response surface approach. Antimicrob Agents Chemother 46 (2002) 2982-2989
22. Hamilton J.D., and Elliott D.M. Combined activity of amphotericin B and 5-fluorocytosine against Cryptococcus neoformans in vitro and in vivo in mice. J Infect Dis 131 (1975) 129-137
23. Schwarz P., Janbon G., Dromer F., Lortholary O., and Dannaoui E. Combination of amphotericin B with flucytosine is active in vitro against flucytosine-resistant isolates of Cryptococcus neoformans. Antimicrob Agents Chemother 51 (2007) 383-385
24. Schwarz P., Dromer F., Lortholary O., and Dannaoui E. Efficacy of amphotericin B in combination with flucytosine against flucytosine-susceptible or flucytosine-resistant isolates of Cryptococcus neoformans during disseminated murine cryptococcosis. Antimicrob Agents Chemother 50 (2006) 113-120
25. Saag M.S., Cloud G.A., Graybill J.R., Sobel J.D., Tuazon C.U., Johnson P.C., et al. A comparison of itraconazole versus fluconazole as maintenance therapy for AIDS-associated cryptococcal meningitis. National Institute of Allergy and Infectious Diseases Mycoses Study Group. Clin Infect Dis 28 (1999) 291-296
26. Dromer F., Mathoulin-Pelissier S., Launay O., and Lortholary O. Determinants of disease presentation and outcome during cryptococcosis: the CryptoA/D study. PLoS Med 4 (2007) e21
27. Larsen R.A., Bauer M., Thomas A.M., and Graybill J.R. Amphotericin B and fluconazole, a potent combination therapy for cryptococcal meningitis. Antimicrob Agents Chemother 48 (2004) 985-991
28. Pappas PG NT, Chetchotisakd P, Larsen R, Manosuthi W, Filler S. Fluconazole plus amphotericin B(AmB) versus AmB alone for primary treatment of AIDS-associated cryptococcal meningitis: results of a phase II trial. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago (USA); 2007; Abstract M-626.
29. Nguyen M.H., Barchiesi F., McGough D.A., Yu V.L., and Rinaldi M.G. In vitro evaluation of combination of fluconazole and flucytosine against Cryptococcus neoformans var. neoformans. Antimicrob Agents Chemother 39 (1995) 1691-1695
30. Schwarz P., Dromer F., Lortholary O., and Dannaoui E. In vitro interaction of flucytosine with conventional and new antifungals against Cryptococcus neoformans clinical isolates. Antimicrob Agents Chemother 47 (2003) 3361-3364
31. Barchiesi F., Schimizzi A.M., Caselli F., Giannini D., Camiletti V., Fileni B., et al. Activity of the new antifungal triazole, posaconazole, against Cryptococcus neoformans. J Antimicrob Chemother 48 (2001) 769-773
32. Dannaoui E., Lortholary O., Raoux D., Bougnoux M.E., Galeazzi G., Lawrence C., et al. Comparative in vitro activities of caspofungin and micafungin, determined using the method of the European Committee on Antimicrobial Susceptibility Testing, against yeast isolates obtained in France in 2005-2006. Antimicrob Agents Chemother 52 (2008) 778-781
33. Franzot S.P., and Casadevall A. Pneumocandin L-743,872 enhances the activities of amphotericin B and fluconazole against Cryptococcus neoformans in vitro. Antimicrob Agents Chemother 41 (1997) 331-336
34. Singh N., Limaye A.P., Forrest G., Safdar N., Munoz P., Pursell K., et al. Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study. Transplantation 81 (2006) 320-326
35. Marr K.A., Boeckh M., Carter R.A., Kim H.W., and Corey L. Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis 39 (2004) 797-802
36. Maertens J., Glasmacher A., Herbrecht R., Thiebaut A., Cordonnier C., Segal B.H., et al. Multicenter, noncomparative study of caspofungin in combination with other antifungals as salvage therapy in adults with invasive aspergillosis. Cancer 107 (2006) 2888-2897
37. Kontoyiannis D.P., Hachem R., Lewis R.E., Rivero G.A., Torres H.A., Thornby J., et al. Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies. Cancer 98 (2003) 292-299
38. Aliff T.B., Maslak P.G., Jurcic J.G., Heaney M.L., Cathcart K.N., Sepkowitz K.A., et al. Refractory Aspergillus pneumonia in patients with acute leukemia: successful therapy with combination caspofungin and liposomal amphotericin. Cancer 97 (2003) 1025-1032
39. Caillot D., Thiebaut A., Herbrecht R., de Botton S., Pigneux A., Bernard F., et al. Liposomal amphotericin B in combination with caspofungin for invasive aspergillosis in patients with hematologic malignancies: a randomized pilot study (Combistrat trial). Cancer 110 (2007) 2740-2746
40. Lortholary O. Associations d'antifongiques. Conférence de consensus commune SFAR, SPILF, SRLF. Ann Fr Anesth Reanim (2004) 60-70 numéro spécial
41. Kontoyiannis D.P., Boktour M., Hanna H., Torres H.A., Hachem R., and Raad I.I. Itraconazole added to a lipid formulation of amphotericin B does not improve outcome of primary treatment of invasive aspergillosis. Cancer 103 (2005) 2334-2337
42. Philip A., Odabasi Z., Rodriguez J., Paetznick V.L., Chen E., Rex J.H., et al. In vitro synergy testing of anidulafungin with itraconazole, voriconazole, and amphotericin B against Aspergillus spp. and Fusarium spp. Antimicrob Agents Chemother 49 (2005) 3572-3574
43. Perea S., Gonzalez G., Fothergill A.W., Kirkpatrick W.R., Rinaldi M.G., and Patterson T.F. In vitro interaction of caspofungin acetate with voriconazole against clinical isolates of Aspergillus spp. Antimicrob Agents Chemother 46 (2002) 3039-3041
44. Cacciapuoti A., Halpern J., Mendrick C., Norris C., Patel R., and Loebenberg D. Interaction between posaconazole and caspofungin in concomitant treatment of mice with systemic Aspergillus infection. Antimicrob Agents Chemother 50 (2006) 2587-2590
45. Johnson M.D., MacDougall C., Ostrosky-Zeichner L., Perfect J.R., and Rex J.H. Combination antifungal therapy. Antimicrob Agents Chemother 48 (2004) 693-715
46. MacCallum D.M., Whyte J.A., and Odds F.C. Efficacy of caspofungin and voriconazole combinations in experimental aspergillosis. Antimicrob Agents Chemother 49 (2005) 3697-3701
47. Arikan S., Lozano-Chiu M., Paetznick V., and Rex J.H. In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp. Antimicrob Agents Chemother 46 (2002) 245-247
48. Clemons K.V., Espiritu M., Parmar R., and Stevens D.A. Comparative efficacies of conventional amphotericin b, liposomal amphotericin B (AmBisome), caspofungin, micafungin, and voriconazole alone and in combination against experimental murine central nervous system aspergillosis. Antimicrob Agents Chemother 49 (2005) 4867-4875
49. Imai J., Singh G., Fernandez B., Clemons K.V., and Stevens D.A. Efficacy of Abelcet and caspofungin, alone or in combination, against CNS aspergillosis in a murine model. J Antimicrob Chemother 56 (2005) 166-171
50. Sionov E., Mendlovic S., and Segal E. Efficacy of amphotericin B or amphotericin B-intralipid in combination with caspofungin against experimental aspergillosis. J Infect 53 (2006) 131-139
51. Dennis C.G., Greco W.R., Brun Y., Youn R., Slocum H.K., Bernacki R.J., et al. Effect of amphotericin B and micafungin combination on survival, histopathology, and fungal burden in experimental aspergillosis in the p47phox-/- mouse model of chronic granulomatous disease. Antimicrob Agents Chemother 50 (2006) 422-427
52. Meletiadis J., Petraitis V., Petraitiene R., Lin P., Stergiopoulou T., Kelaher A.M., et al. Triazole-polyene antagonism in experimental invasive pulmonary aspergillosis: in vitro and in vivo correlation. J Infect Dis 194 (2006) 1008-1018
53. Perkhofer S., Lugger H., Dierich M.P., and Lass-Florl C. Posaconazole enhances the activity of amphotericin B against Aspergillus hyphae in vitro. Antimicrob Agents Chemother 51 (2007) 791-793
54. Denning D.W., and Stevens D.A. Antifungal and surgical treatment of invasive aspergillosis: review of 2,121 published cases. Rev Infect Dis 12 (1990) 1147-1201
55. Walsh T.J., Anaissie E.J., Denning D.W., Herbrecht R., Kontoyiannis D.P., Marr K.A., et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 46 (2008) 327-360
56. Herbrecht R., Flückiger U., Gachot B., Ribaud R., Thiebaud A., and Cordonnier C. Treatment of invasive Candida and invasive Aspergillus in adult haematological patients. Eur J Cancer Suppl. 5 (2007) 49-59
57. Cacciapuoti A., Gurnani M., Halpern J., Norris C., Patel R., and Loebenberg D. Interaction between posaconazole and amphotericin B in concomitant treatment against Candida albicans in vivo. Antimicrob Agents Chemother 49 (2005) 638-642
58. Olson J.A., Adler-Moore J.P., Smith P.J., and Proffitt R.T. Treatment of Candida glabrata infection in immunosuppressed mice by using a combination of liposomal amphotericin B with caspofungin or micafungin. Antimicrob Agents Chemother 49 (2005) 4895-4902
59. Medoff G., Comfort M., and Kobayashi G.S. Synergistic action of amphotericin B and 5-fluorocytosine against yeast-like organisms. Proc Soc Exp Biol Med 138 (1971) 571-574
60. Choukroun G., Thirion M., Lortholary O., Scatton O., Conti F., Calmus Y., et al. Antifungal alternatives for invasive candidiasis refractory to caspofungin in liver transplant recipients: a report of two cases. Transplantation 82 (2006) 1385-1386